TD Cowen analyst Phil Nadeau maintained a Buy rating on Vir Biotechnology (VIR – Research Report) today. The company’s shares closed yesterday at $9.77.
According to TipRanks, Nadeau is a 4-star analyst with an average return of 5.5% and a 45.02% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Biogen, and BioMarin Pharmaceutical.
In addition to TD Cowen, Vir Biotechnology also received a Buy from H.C. Wainwright’s Patrick Trucchio in a report issued on May 7. However, on May 2, J.P. Morgan maintained a Hold rating on Vir Biotechnology (NASDAQ: VIR).
The company has a one-year high of $27.48 and a one-year low of $7.61. Currently, Vir Biotechnology has an average volume of 1.02M.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VIR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vir Biotechnology (VIR) Company Description:
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
